ClinicalTrials.gg
CompletedNCT00457340CLARIDIUpdated Feb 18, 2021

Atorvastatin For The Reduction Of Ventricular Arrhythmias

A Phase 4 interventional study of Atorvastatin 80mg in Arrhythmia, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 10 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-18.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
220
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 51 studies in Arrhythmias, Cardiac with a site in Belgium — 10 open to participants now, 14 under way, none of them phase 3. Arrhythmias, Cardiac · Belgium.

Enrollment
19th of 31
220 · median 269
Started
2000
the only one that year
Phase 4
Only one
of the 51
Registered
8th of 51
by date

Among the 51 studies in Arrhythmias, Cardiac with a site in Belgium, this one is the 19th largest by enrollment of the 31 interventional ones that give a count, is the only one that started in 2000, is the only one in phase 4, and was the 8th registered.

Arrhythmias, Cardiac

1,051 studies on the registry are indexed under Arrhythmias, Cardiac; 235 are open to participants now.

Browse Arrhythmias, Cardiac studies →

Open to participants now

10 of the 51 studies in Arrhythmias, Cardiac with a site in Belgium are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 166 Arrhythmias, Cardiac studies recruiting now, 118 (71%) set no upper age limit and 13 (8%) stop at 75 or younger; 31 take children under 18; 26 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Arrhythmias, Cardiac with a site in Belgium, or all of them as a file.
02

Study summary

To assess in patients with CAD [coronary artery disease] and an implantable defibrillator the effect of atorvastatin 80 mg versus placebo on the first recurrence of a ventricular arrhythmia (ventricular tachycardia or ventricular fibrillation requiring ICD [implantable cardioverter defibrillator] intervention) within one year after randomization.

03

Conditions studied

  • Arrhythmia

Keywords

  • Tachycardia, Ventricular
  • Ventricular Fibrillation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Eligible subjects were male or female subjects, age >18 years, with clinically documented coronary artery disease and life-threatening ventricular arrhythmias who met the following criteria:
  • Were scheduled for an ICD implantation or had an ICD implantation within 1 month, according to the class I American College of Cardiology/American Heart Association (ACC/AHA) practice guidelines for ICD therapy

OR

  • Were already treated with an ICD for a class I ACC/AHA indication for more than one month, provided they received at least one appropriate ICD intervention (shock or antitachycardia pacing (ATP) for ventricular tachycardia or ventricular fibrillation) during the preceding six months

Exclusion criteria

Exclusion Criteria:

  • Patients with ventricular arrhythmias in the acute phase of myocardial infarction (first 48 hours).
  • Patients with incessant ventricular tachycardia.
  • Patients with ventricular arrhythmias without underlying coronary artery disease.
  • Patients with a transient or reversible cause of ventricular arrhythmias (including significant electrolyte disturbances or drug induced proarrhythmia).
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
220 participants

Interventions

06

What researchers measure

Primary outcomes

  1. To assess in patients with CAD and an implantable defibrillator the effect of atorvastatin 80 mg versus placebo on the first recurrence of a ventricular arrhythmia after randomisation.

Secondary outcomes

  1. Combined total mortality and major cardiovascular events.

  2. Major cardiovascular events include acute myocardial infarction, stroke and PTCA [percutaneous coronary angioplasty] (with or without stenting) or CABG [coronary artery bypass graft] (CABG already foreseen at the moment of randomization).

  3. Total number of appropriate ICD interventions for ventricular arrhythmias and total number of episodes of electrical storm.

  4. An episode of electrical storm is defined as the occurrence within 24 hours of three or more ventricular arrhythmias requiring ICD intervention.

  5. Combined total mortality, major cardiovascular events and total number of appropriate ICD interventions for ventricular arrhythmias.

07

Study locations

10 sites
  • Pfizer Investigational Site
    Aalst, Belgium
  • Pfizer Investigational Site
    Antwerpen, Belgium
  • Pfizer Investigational Site
    Brugge, Belgium
  • Pfizer Investigational Site
    Edegem, Belgium
  • Pfizer Investigational Site
    Gent, Belgium
  • Pfizer Investigational Site
    Hasselt, Belgium
  • Pfizer Investigational Site
    Leuven, Belgium
  • Pfizer Investigational Site
    Athens, Greece
  • Pfizer Investigational Site
    Crete, Greece
  • Pfizer Investigational Site
    RIO Patra, Greece
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2000 and a completion of Sep 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2007
First posted
Apr 6, 2007
Start
Feb 2000
CompletionActual
Sep 2004
Last update
Feb 18, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00457340
Responsible party
Sponsor
First posted
Apr 6, 2007
Start date
Feb 2000
Completion
Sep 2004
Last update
Feb 18, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atorvastatin

Start the discussion